Kathryn R. Wagner has devoted her career to improving treatment for those affected by neurological disorders.  She received her MD and PhD in molecular neuroscience from the Johns Hopkins School of Medicine.   Following residency training in neurology and clinical fellowships in neuromuscular and neurogenetic disorders, she joined the faculty of the Johns Hopkins School of Medicine where she rose to Professor of Neurology and Neuroscience. Her translational research laboratory received continuous NIH funding for over 20 years, elucidating the role of myostatin in promoting muscle regeneration and reducing fibrosis in animal models of disease.  She was the founding director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute where she cared for pediatric and adult individuals with neuromuscular disorders and conducted investigator and industry initiated clinical trials.  In order to advance drug development for rare disorders, she transitioned to industry where she served as Vice President, Global Head of Neuromuscular Diseases at Roche leading late-stage programs in Duchenne Muscular Dystrophy (Elevidys) and Spinal Muscular Atrophy (Evrysdi), obtaining multiple regulatory approvals.  More recently, she served as Vice President, Global Head of Translational Medicine, Neuroscience at Novartis where she directed early development of a broad portfolio.  Currently, Kathryn is Chair of the Board of Trustees of TREAT-NMD Alliances and Professor Emerita at the Johns Hopkins School of Medicine.